Home › Research › TREM2 and immune genetics
Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology
Suárez-Calvet M, Morenas-Rodríguez E, Kleinberger G, Schlepckow K, Araque Caballero MÁ, Franzmeier N, Capell A, Fellerer K et al.. Molecular neurodegeneration, 2019-01-10
Topic: Brain proteins, microglia and lab models
Plain-language summary
Background TREM2 is a transmembrane receptor that is predominantly expressed by microglia in the central nervous system. Rare variants in the TREM2 gene increase the risk for late-onset Alzheimer's disease (AD). Soluble TREM2 (sTREM2) resulting from shedding of the TREM2 ectodomain can be detected in the cerebrospinal fluid (CSF) and is a surrogate measure of TREM2-mediated microglia function.
What this study adds
Evidence grade: Moderate
This is a cross-sectional study of 1,027 participants. Soluble TREM2 in spinal fluid is a stand-in measure of how microglia, the brain's immune cells, are working. This cross-sectional study grouped people at early stages of Alzheimer's, with and without symptoms, using the NIA-AA biomarker framework.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Suárez-Calvet, M., Morenas-Rodríguez, E., Kleinberger, G., Schlepckow, K., MÁ, A. C., Franzmeier, N., et al. (2019). Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology. Molecular neurodegeneration. https://doi.org/10.1186/s13024-018-0301-5
Vancouver
Suárez-Calvet M, Morenas-Rodríguez E, Kleinberger G, Schlepckow K, MÁ AC, Franzmeier N, et al. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology. Molecular neurodegeneration. 2019. doi:10.1186/s13024-018-0301-5. PMID: 30630532.
BibTeX
@article{suarezcalvet2019-30630532,
author = {Suárez-Calvet, M. and Morenas-Rodríguez, E. and Kleinberger, G. and Schlepckow, K. and MÁ, Araque Caballero and Franzmeier, N. and Capell, A. and Fellerer, K. and others},
title = {{Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology}},
journal = {Molecular neurodegeneration},
year = {2019},
doi = {10.1186/s13024-018-0301-5},
pmid = {30630532},
url = {https://doi.org/10.1186/s13024-018-0301-5}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Rare variants in the TREM2 gene increase the risk for late-onset Alzheimer's disease (AD).
- Soluble TREM2 (sTREM2) resulting from shedding of the TREM2 ectodomain can be detected in the cerebrospinal fluid (CSF) and is a surrogate measure of TREM2-mediated microglia function.
- CSF sTREM2 has been previously reported to increase at different clinical stages of AD, however, alterations in relation to Amyloid β-peptide (Aβ) deposition or additional pathological processes in the amyloid cascade (such as tau pathology or neurodegeneration) remain unclear.
- In the current cross-sectional study, we employed the biomarker-based classification framework recently proposed by the NIA-AA consensus guidelines, in combination with clinical staging, in order to examine the CSF sTREM2 alterations at early asymptomatic and symptomatic stages of AD.
Why it matters
Soluble TREM2 in spinal fluid is a stand-in measure of how microglia, the brain's immune cells, are working. This cross-sectional study grouped people at early stages of Alzheimer's, with and without symptoms, using the NIA-AA biomarker framework. It reports that sTREM2 is raised early and that the rise is associated with tau-related neurodegeneration but not with amyloid-β pathology. The stored text gives no figures, and as a one-time observational comparison it shows association rather than cause and tests no treatment.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Study designcross-sectional
- Participants1,027
- Evidence strengthModerate
How this study scored 69/100
Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Molecular neurodegeneration) |
| Journal's citation record | 2 / 4 | Molecular Neurodegeneration: journal h-index 164 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,027 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 348 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 38.7 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 5 / 6 | Cited 20.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 44 other studies in this library |
| Still being cited | 3 / 4 | Cited 154 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Christian Haass: h-index 139 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Washington University in St. Louis: institution h-index 1,962 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 13 institution(s) in 4 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 30630532) |
| Free to read | 2 / 2 | Free to read |
| Total | 69 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s13024-018-0301-5
- PubMed: 30630532
- Original source →
- Free full text: Molecular Neurodegeneration →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 47.
Later studies that cite this one
44 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in TREM2 and immune genetics from nearby years
Also tagged “r47h”
363 studies in the library carry the topic tag “r47h”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 363 tagged studies.